Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

NANO co-delivery of quercetin and alantolactone promotes Anti-tumor response through synergistic immunogenic cell death for microsatellite-stable colorectal cancer

A technology of inulin and immune cells, used in antitumor drugs, drug delivery, emulsion delivery, etc.

Pending Publication Date: 2022-02-11
THE UNIV OF NORTH CAROLINA AT CHAPEL HILL
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately for colorectal cancer patients, approximately 95% of the patient population does not respond to PD-1 / PD-L1 blockade therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • NANO co-delivery of quercetin and alantolactone promotes Anti-tumor response through synergistic immunogenic cell death for microsatellite-stable colorectal cancer
  • NANO co-delivery of quercetin and alantolactone promotes Anti-tumor response through synergistic immunogenic cell death for microsatellite-stable colorectal cancer
  • NANO co-delivery of quercetin and alantolactone promotes Anti-tumor response through synergistic immunogenic cell death for microsatellite-stable colorectal cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Nanoscale co-delivery of quercetin and inulin against microsatellite-stable colorectal cancer promoting antitumor response via synergistic immunogenic cell death

[0068] 1.1 Overview

[0069] Microsatellite stable colorectal cancer (CRC) is known to be resistant to immunotherapy. The combination of quercetin (Q) and inulin (A) was found to induce synergistic immunogenic cell death (ICD) at a molar ratio of 1:4 (Q:A). To achieve proportional loading and delivery, micellar delivery of Q and A (QA-M) with high encapsulation efficiency and optimal ratio of drug loading was developed. QA-M achieved prolonged blood circulation and enhanced tumor accumulation for both drugs. More importantly, QA-M retained the desired drug ratio in tumors (molar ratio of Q to A = 1:4) at 2 and 4 hours after intravenous injection of synergistic immunotherapy. Treatment by QA-M significantly inhibited tumor growth in murine orthotopic CRC when compared to the combination of PBS and free drug...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
critical micelle concentration (mass)aaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

Disclosed are micellar formulations comprising a synergistic combination of quercetin and alantolactone and their use for treating a cancer, including microsatellite-stable colorectal cancer (CRC), which otherwise is resistant to immunotherapy. The combination of quercetin and alantolactone was found to induce synergistic immunogenic cell death (ICD) at synergistic ratiometric micellar loadings.

Description

[0001] Federally funded research or development [0002] This invention was made with government support under Grant No. CA198999 awarded by the National Institutes of Health. The government has certain rights in this invention. Background technique [0003] Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide, affecting both women and men. It is the third leading cause of death in the United States. Surgical resection, chemotherapy (eg, CapeOX, FOLFOX, or FOLFIRI) and radiation therapy are standard clinical treatments. However, these regimens are not effective for advanced disease, as the high recurrence rate after surgery is still troublesome. In 2017, more than 95,520 new cases of colon cancer and approximately 40,000 new cases of rectal cancer were reported in the United States alone. Although colonoscopy and other screening and preventive measures have improved survival, fewer than 40% of CRCs can be diagnosed at the localized stage. The fiv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K31/07A61P35/00
CPCA61P35/00A61K31/352A61K31/343A61K9/107A61K47/22A61K47/24A61K9/0019A61K2300/00A61K9/1075A61K31/365A61K47/10
Inventor 力夫·黄张婧申丽玫
Owner THE UNIV OF NORTH CAROLINA AT CHAPEL HILL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com